Ginkgo Bioworks Holdings (DNABW) Asset Utilization Ratio (2021 - 2026)
Ginkgo Bioworks Holdings (DNABW) reported Asset Utilization Ratio of 0.13 for Q1 2026, down 22.88% on a YoY basis from 0.17 in Q1 2025, and down 5.32% quarter-over-quarter from 0.14 in Q4 2025.
Ginkgo Bioworks Holdings (DNABW) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Asset Utilization Ratio for 6 years, with the latest figure at 0.13 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio fell 22.88% year-over-year to 0.13; the trailing twelve-month figure through Mar 2026 stood at 0.13 (down 22.88% YoY), and the FY2025 full-year result was 0.14, down 8.68% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.13, down from 0.14 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.27 in Q3 2022, with the low at 0.11 in Q2 2024.
- Historically, Asset Utilization Ratio has averaged 0.17 across 5 years, with a median of 0.15 in 2023.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio soared 245.3% — and 2023, when it plunged 47.98%.
- Ginkgo Bioworks Holdings' Asset Utilization Ratio stood at 0.22 in 2022, then plunged by 37.12% to 0.14 in 2023, then gained by 16.62% to 0.16 in 2024, then declined by 12.72% to 0.14 in 2025, then declined by 5.32% to 0.13 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.13 (Q1 2026), 0.14 (Q4 2025), and 0.14 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | - | - | 16.38 Mn | 0.13 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.13 |
| Dec 31, 2025 | 0.14 |
| Sep 30, 2025 | 0.14 |
| Jun 30, 2025 | 0.17 |
| Mar 31, 2025 | 0.17 |
| Dec 31, 2024 | 0.16 |
| Sep 30, 2024 | 0.14 |
| Jun 30, 2024 | 0.11 |
| Mar 31, 2024 | 0.13 |
| Dec 31, 2023 | 0.14 |
| Sep 30, 2023 | 0.15 |
| Jun 30, 2023 | 0.14 |
| Mar 31, 2023 | 0.16 |
| Dec 31, 2022 | 0.22 |
| Sep 30, 2022 | 0.27 |
| Jun 30, 2022 | 0.27 |
| Mar 31, 2022 | 0.21 |
| Dec 31, 2021 | 0.15 |
| Sep 30, 2021 | 0.10 |
| Jun 30, 2021 | 0.08 |